Literature DB >> 30193264

Out-of-Pocket Costs for Infliximab and Its Biosimilar for Rheumatoid Arthritis Under Medicare Part D.

Jinoos Yazdany1, R Adams Dudley2, Grace A Lin2, Randi Chen3, Chien-Wen Tseng4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30193264      PMCID： PMC6142992          DOI： 10.1001/jama.2018.7316

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  2 in total

1.  Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.

Authors:  Jinoos Yazdany; R Adams Dudley; Randi Chen; Grace A Lin; Chien-Wen Tseng
Journal:  Arthritis Rheumatol       Date:  2015-06       Impact factor: 10.995

2.  Obstacles to the Adoption of Biosimilars for Chronic Diseases.

Authors:  Aaron Hakim; Joseph S Ross
Journal:  JAMA       Date:  2017-06-06       Impact factor: 56.272
  2 in total
  7 in total

1.  Failure to Launch: Biosimilar Sales Continue to Fall Flat in the United States.

Authors:  Jinoos Yazdany
Journal:  Arthritis Rheumatol       Date:  2020-04-23       Impact factor: 10.995

Review 2.  2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.

Authors:  Michael M Ward; Atul Deodhar; Lianne S Gensler; Maureen Dubreuil; David Yu; Muhammad Asim Khan; Nigil Haroon; David Borenstein; Runsheng Wang; Ann Biehl; Meika A Fang; Grant Louie; Vikas Majithia; Bernard Ng; Rosemary Bigham; Michael Pianin; Amit Aakash Shah; Nancy Sullivan; Marat Turgunbaev; Jeff Oristaglio; Amy Turner; Walter P Maksymowych; Liron Caplan
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-08-21       Impact factor: 4.794

3.  2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.

Authors:  Michael M Ward; Atul Deodhar; Lianne S Gensler; Maureen Dubreuil; David Yu; Muhammad Asim Khan; Nigil Haroon; David Borenstein; Runsheng Wang; Ann Biehl; Meika A Fang; Grant Louie; Vikas Majithia; Bernard Ng; Rosemary Bigham; Michael Pianin; Amit Aakash Shah; Nancy Sullivan; Marat Turgunbaev; Jeff Oristaglio; Amy Turner; Walter P Maksymowych; Liron Caplan
Journal:  Arthritis Rheumatol       Date:  2019-08-22       Impact factor: 15.483

Review 4.  Update on Biosimilar Insulins: A US Perspective.

Authors:  Rong M Zhang; Ritika Puri; Janet B McGill
Journal:  BioDrugs       Date:  2020-08       Impact factor: 7.744

5.  Assessment of Expected Out-of-Pocket Spending for Rheumatoid Arthritis Biologics Among Patients Enrolled in Medicare Part D, 2010-2019.

Authors:  Alexandra Erath; Stacie B Dusetzina
Journal:  JAMA Netw Open       Date:  2020-04-01

6.  Medicare Part D and Cost-Sharing for Antiretroviral Therapy and Preexposure Prophylaxis.

Authors:  Chien-Wen Tseng; R Adams Dudley; Randi Chen; Rochelle P Walensky
Journal:  JAMA Netw Open       Date:  2020-04-01

7.  Patterns of Tumor Necrosis Factor Inhibitor (TNFi) Biosimilar Use Across United States Rheumatology Practices.

Authors:  Nick Bansback; Jeffrey R Curtis; Jie Huang; Zeling He; Michael Evans; Tracy Johansson; Kaleb Michaud; Gabriela Schmajuk; Katherine P Liao
Journal:  ACR Open Rheumatol       Date:  2020-01-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.